Sign In
Buy AMGN
$338.22
+9.96 (+3.03%)
At Close: Jun 03, 2026
Amgen Q1 revenue beats expectations, profit declines
09:03pm, Wednesday, 27'th Apr 2022 MarketWatch
Amgen Inc. on Wednesday logged better-than-expected revenue and a decline in profit in the first quarter.
Amgen Inc. (AMGN) CEO Bob Bradway on Q1 2022 Results - Earnings Call Transcript
08:27pm, Wednesday, 27'th Apr 2022
Amgen Inc. (NASDAQ:AMGN ) Q1 2022 Results Conference Call April 27, 2022 5:00 PM ET Company Participants Arvind Sood - VP, IR Bob Bradway - Chairman and CEO Peter Griffith - CFO Murdo Gordon - EVP, Gl
Amgen (AMGN) Surpasses Q1 Earnings and Revenue Estimates
07:05pm, Wednesday, 27'th Apr 2022
Amgen (AMGN) delivered earnings and revenue surprises of 0.71% and 2.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Amgen Q1 revenue beats expectations, profit declines
05:03pm, Wednesday, 27'th Apr 2022
Amgen Inc. on Wednesday logged better-than-expected revenue and a decline in profit in the first quarter.
Amgen says IRS seeks another $5.1 billion in back taxes
04:34pm, Wednesday, 27'th Apr 2022
Amgen Inc on Wednesday said the U.S. Internal Revenue Service (IRS) is seeking additional back taxes of $5.1 billion, plus interest and penalties, related to the drugmaker's 2013 to 2015 accounting fo
Molecular Partners shares tumble 37% after Amgen returns rights to tumor treatment candidate
08:02am, Wednesday, 27'th Apr 2022
Shares of Molecular Partners Inc. MOLN, -36.67% slid 37.3% in premarket trading on Wednesday, the day after the company said Amgen Inc. AMGN, -0.91% returned the global rights to an investigational on
Molecular Partners Regains Rights To Early-Stage Cancer Asset From Amgen
06:19am, Wednesday, 27'th Apr 2022
Molecular Partners AG's (NASDAQ: MOLN) collaborating partner Amgen Inc (NASDAQ: AMGN) for MP0310 (AMG 506) will return the global rights of MP0310 to Molecular Partners following a strategic pipe
Drug/Biotech Stocks' Apr 27 Q1 Earnings Roster: GSK, AMGN & More
03:44pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.
Healthcare ETFs in Focus Ahead of Q1 Earnings
03:15pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfo
Healthcare ETFs in Focus Ahead of Q1 Earnings
12:47pm, Tuesday, 26'th Apr 2022
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfo
What Stocks to Buy That Should Do Well in a Recession — Our 7 Top Picks
06:30am, Tuesday, 26'th Apr 2022
Americans will still use brand names, buy groceries and clothes, get healthcare services and pay their utilities during a recession. That's good news for these 7 recession-resistant stocks to buy.
These 2 Nasdaq Stocks Are Favorites Among Defensive Investors
07:28pm, Monday, 25'th Apr 2022 The Motley Fool
You would be hard-pressed to find more-solid companies.
Gilead (GILD) to Report Q1 Earnings: Is a Beat in the Cards?
03:49pm, Monday, 25'th Apr 2022 Zacks Investment Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) first-quarter 2022 results.
These 2 Nasdaq Stocks Are Favorites Among Defensive Investors
03:28pm, Monday, 25'th Apr 2022
You would be hard-pressed to find more-solid companies.
2 Top Biotech Stocks to Buy Right Now
02:15pm, Monday, 25'th Apr 2022 The Motley Fool
The encouraging pharmaceutical industry outlook bodes well for both of these blue-chip pharma stocks.
